Internal Medicine, Nephrology · New York, NY
NPI
1588633135
Since 2006
Specialty
Internal Medicine, Nephrology
Code 207RN0300X
Group practices
1
Medicare group memberships
Hospitals
0
Hospital affiliations
139 Centre Street, Suite 703
New York, NY, 10013
Phone (212) 966-0808
Groups this clinician bills Medicare through
Medicare paid, 2024
$141K
2,150 services
Medicare patients, 2024
407
Average age 79
Drug cost, 2024
$18.6M
66,389 prescriptions
Company payments, 2025
$10K
From 30 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Wei Y Sun was code 99213 (office e&m - established), 664 times for 305 patients. In total Wei Y Sun billed 2,150 services in 28 codes, and Medicare paid $141K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2018-09-26.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 664 | 305 | $73.91 | $49K |
| 81003 Clinical Chemistry | Office | 307 | 184 | $2.20 | $675 |
| 82570 Clinical Chemistry | Office | 301 | 181 | $5.08 | $1,529 |
| 99214 Office E&M - Established | Office | 134 | 79 | $98.63 | $13K |
| 90960 ESRD Related Services (not dialysis) | Office | 134 | 17 | $305.58 | $41K |
| 36415 Venipuncture Blood Collection | Office | 120 | 79 | $8.65 | $1,038 |
| 81000 Clinical Chemistry | Office | 69 | 55 | $3.94 | $272 |
| 76857 Ultrasound - Abdomen and Pelvis | Office | 62 | 62 | $30.39 | $1,884 |
| 76770 Ultrasound - Abdomen and Pelvis | Office | 62 | 62 | $90.28 | $5,598 |
| 96372 Injection Administration | Office | 57 | 22 | $12.44 | $709 |
| 99212 Office E&M - Established | Office | 33 | 14 | $50.79 | $1,676 |
| 99442 Telephone Services | Office | 33 | 27 | $67.67 | $2,233 |
| 99426 Chronic, Principal, and Transitional Care Management | Office | 32 | 30 | $52.03 | $1,665 |
| G0420 Face-to-face educational services related to the care of chronic kidney disease; individual, per session, per one hour | Office | 28 | 25 | $95.37 | $2,670 |
| 99204 Office E&M - New | Office | 28 | 28 | $133.84 | $3,748 |
By year: 2022 $271K for 3,227 services; 2023 $188K for 2,698 services; 2024 $141K for 2,150 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 307 | 184 | $2.20 | $675 |
| 82570 Clinical Chemistry | 301 | 181 | $5.08 | $1,529 |
| 36415 Venipuncture Blood Collection | 120 | 79 | $8.65 | $1,038 |
| 81000 Clinical Chemistry | 69 | 55 | $3.94 | $272 |
Medicare prescription drug claims, 2024
In 2024, the drug Wei Y Sun prescribed most often to Medicare patients was Vascepa (Icosapent Ethyl), with 7,033 prescriptions and refills. In total Wei Y Sun wrote 66,389 Medicare prescriptions that cost $18.6M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Vascepa Icosapent Ethyl | 7,033 | 7,865 | 962 | $2.6M |
| Olmesartan Medoxomil Generic | 3,560 | 4,019 | 521 | $18K |
| Farxiga Dapagliflozin Propanediol | 3,361 | 3,979 | 561 | $2.2M |
| Kerendia Finerenone | 3,330 | 3,764 | 519 | $2.4M |
| Losartan Potassium Generic | 3,018 | 3,593 | 474 | $13K |
| Amlodipine Besylate Generic | 2,095 | 2,447 | 344 | $7,207 |
| Jardiance Empagliflozin | 2,074 | 2,309 | 318 | $1.3M |
| Calcitriol Generic | 1,821 | 2,212 | 257 | $24K |
| Tamsulosin Hcl Generic | 1,689 | 1,985 | 253 | $8,581 |
| Potassium Citrate Er Potassium Citrate | 1,563 | 1,723 | 223 | $34K |
| Hydralazine Hcl Generic | 1,496 | 1,672 | 218 | $9,814 |
| Gemtesa Vibegron | 1,456 | 1,609 | 253 | $766K |
| Nifedipine Er Nifedipine | 1,342 | 1,525 | 179 | $10K |
| Tradjenta Linagliptin | 1,338 | 1,532 | 229 | $779K |
| Allopurinol Generic | 1,327 | 1,611 | 203 | $5,388 |
Brand drugs: 26,022 claims; generic drugs: 39,818 claims; opioid claims: 24.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Wei Y Sun $10K ($10K in general payments such as food, travel and fees) from 30 companies. The largest payer was Calliditas Therapeutics US Inc. with $5,001.
| Company | Payments | Amount |
|---|---|---|
| Calliditas Therapeutics US Inc. | 12 | $5,001 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 30 | $653 |
| AstraZeneca Pharmaceuticals LP AZN | 24 | $612 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 18 | $401 |
| Sumitomo Pharma America, Inc. 4506.T | 15 | $337 |
| Novartis Pharmaceuticals Corporation NVS | 24 | $321 |
| Travere Therapeutics, Inc. TVTX | 9 | $316 |
| Amgen Inc. AMGN | 10 | $273 |
| ANI Pharmaceuticals, Inc. ANIP | 14 | $265 |
| Mallinckrodt Hospital Products Inc. | 7 | $244 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.